Deals this week: SciVision Biotech, Symic Biomedical, Palladio Biosciences
Taiwanese company SciVision Biotech intends to raise up to $30m in gross proceeds through a public offering of overseas secured convertible corporate bonds.
The proceeds from the three-year bonds will be partly invested in the extension of the company’s plants and partly to repay loans.
Symic Biomedical has completed a series B venture financing round to raise $30m in gross proceeds from existing investors and a new investor named HEDA Ventures.
Based in the US, Symic Biomedical is a biotechnology company that intends to use the proceeds to support its clinical programmes and research activities.
Palladio Biosciences has completed a series A financing round led by Medicxi Ventures (UK) to raise funds.
Palladio is a biopharmaceutical company based in the US.
US-based biopharmaceutical company Achaogen will issue up to five million shares of its common stock to the public in order to raise funds required to primarily develop and prepare for the commercialisation of plazomicin.
Any remaining funds will be utilised for working capital and general corporate purposes.
Underwriters to the offering will be granted a 30-day option to purchase up to an additional 750,000 shares at the offer price.
Based in the US, Achaogen is a biopharmaceutical company focused on multi-drug resistant (MDR) gram-negative infections.